A First Report on [(18)F]FPRGD2 PET/CT Imaging in Multiple Myeloma.

[en] An observational study was set up to assess the feasibility of [(18)F]FPRGD2 PET/CT for imaging patients with multiple myeloma (MM) and to compare its detection rate with low dose CT alone and combined [(18)F]NaF/[(18)F]FDG PET/CT images. Four patients (2 newly diagnosed patients and 2 with relapsed MM) were included and underwent whole-body PET/CT after injection of [(18)F]FPRGD2. The obtained images were compared with results of low dose CT and already available results of a combined [(18)F]NaF/[(18)F]FDG PET/CT. In total, 81 focal lesions (FLs) were detected with PET/CT and an underlying bone destruction or fracture was seen in 72 (89%) or 8 (10%) FLs, respectively. Fewer FLs (54%) were detected by [(18)F]FPRGD2 PET/CT compared to low dose CT (98%) or [(18)F]NaF/[(18)F]FDG PET/CT (70%) and all FLs detected with [(18)F]FPRGD2 PET were associated with an underlying bone lesion. In one newly diagnosed patient, more [(18)F]FPRGD2 positive lesions were seen than [(18)F]NaF/[(18)F]FDG positive lesions. This study suggests that [(18)F]FPRGD2 PET/CT might be less useful for the detection of myeloma lesions in patients with advanced disease as all FLs with [(18)F]FPRGD2 uptake were already detected with CT alone.

Disciplines :

Hematology

Author, co-author :

WITHOFS, Nadia ; Centre Hospitalier Universitaire de Liège - CHU > Service médical de médecine nucléaire et imagerie onco

COUSIN, François

DE PRIJCK, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Service d'hématologie clinique

Bonnet, Christophe ; Université de Liège - ULiège > GIGA-R : Hématologie

Hustinx, Roland ; Université de Liège - ULiège > Département des sciences cliniques > Médecine nucléaire

Gambhir, Sanjiv S.

Beguin, Yves ; Université de Liège - ULiège > GIGA-R : Hématologie

Caers, Jo ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Language :

English

Title :

A First Report on [(18)F]FPRGD2 PET/CT Imaging in Multiple Myeloma.

Publication date :

2017

Journal title :

Contrast Media and Molecular Imaging

ISSN :

1555-4309

eISSN :

1555-4317

Publisher :

John Wiley & Sons, Hoboken, United States - New Jersey

Volume :

2017

Pages :

6162845

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 23 February 2018

Statistics

Number of views

94 (5 by ULiège)

Number of downloads

88 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

S. V. Rajkumar, M. A. Dimopoulos, and A. Palumbo, “International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma,” The Lancet Oncology, vol. 15, no. 12, pp. e538–e548, 2014.
J. Caers, C. F. De Larrea, X. Leleu et al., “The changing landscape of smoldering multiple myeloma: a european perspective,” Oncologist, vol. 21, no. 3, pp. 333–342, 2016.
M. Cavo, E. Terpos, C. Nanni et al., “Role of18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group,” The Lancet Oncology, vol. 18, no. 4, pp. e206–e217, 2017.
Z. Wu, Z.-B. Li, W. Cai et al., “18F-labeled mini-PEG spacered RGDdimer (18F-FPRGD2): synthesis and microPET imaging of αv β3 integrin expression,” European Journal of NuclearMedicine and Molecular Imaging, vol. 34, no. 11, pp. 1823–1831, 2007.
D. Thonon, D. Goblet, E. Goukens et al., “Fully automated preparation and conjugation of N-succinimidyl 4- [18F]fluorobenzoate ([18F]SFB) with RGD peptide using a GEFASTlab synthesizer,” Molecular Imaging and Biology, vol. 13, no. 6, pp. 1088–1095, 2011.
N. Withofs, E. Charlier, P. Simoni et al., “18F-FPRGD2 PET/CT imaging of musculoskeletal disorders,” Annals of Nuclear Medicine, vol. 29, no. 10, pp. 839–847, 2015.
N. Withofs, N. Signolle, J. Somja et al., “18F-FPRGD2 PET/CT imaging of integrin αv β3 in renal carcinomas: correlation with histopathology,” Journal of Nuclear Medicine, vol. 56, no. 3, pp. 361–364, 2015.
N. Withofs, P. Martinive, J. Vanderick et al., “[18F]FPRGD2 PET/CT imaging of integrin αv β3levels in patients with locally advanced rectal carcinoma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 43, no. 4, pp. 654–662, 2016.
R. Haubner, HJ. Wester, U. Reuning, R. Senekowitsch- Schmidtke, B. Diefenbach, and H. Kessler, “Radiolabeled αv β3 integrin antagonists: a new class of tracers for tumor targeting,” Journal of Nuclear Medicine, pp. 40–1061, 1999.
S. M. Weis and D. A. Cheresh, “α integrins in angiogenesis and cancer,” Cold Spring Harbor perspectives in medicine, vol. 1, no. 1, p. a006478, 2011.
F. C. Gaertner, H. Kessler, H.-J. Wester, M. Schwaiger, and A. J. Beer, “Radiolabelled RGD peptides for imaging and therapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 1, pp. S126–S138, 2012.
L. Seguin, J. S. Desgrosellier, S. M. Weis, and D. A. Cheresh, “Integrins and cancer: regulators of cancer stemness,metastasis, and drug resistance,” Trends in Cell Biology, vol. 25, no. 4, pp. 234–240, 2015.
T. J. Wadas, H. Deng, J. E. Sprague, A. Zheleznyak, K. N. Weilbaecher, and C. J. Anderson, “Targeting the αv β3 integrin for small-animal PET/CT of osteolytic bonemetastases,” Journal of Nuclear Medicine, vol. 50, no. 11, pp. 1873–1880, 2009.
K. Cohen, N. Flint, S. Shalev et al., “Thyroid hormone regulates adhesion, migration and matrix metalloproteinase 9 activity via αv β3integrin in myeloma cells,” Oncotarget, vol. 5, no. 15, pp. 6312–6322, 2014.
S. Stucci, M. Tucci, A. Passarelli, and F. Silvestris, “αv β3 integrin: Pathogenetic role in osteotropic tumors,” Critical Reviews in Oncology/Hematology, vol. 96, no. 1, pp. 183–193, 2015.
J. G. Schneider, S. R. Amend, and K. N. Weilbaecher, “Integrins and bone metastasis: Integrating tumor cell and stromal cell interactions,” Bone, vol. 48, no. 1, pp. 54–65, 2011.
J. Caers, U. Günthert, H. De Raeve et al., “The involvement of osteopontin and its receptors inmultiplemyeloma cell survival, migration and invasion in the murine 5T33MMmodel,” British Journal of Haematology, vol. 132, no. 4, pp. 469–477, 2006.
A. Iagaru, E. Mittra, S. S. Yaghoubi et al., “Novel strategy for a cocktail18F-fluoride and18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study,” Journal of Nuclear Medicine, vol. 50, no. 4, pp. 501–505, 2009.
S. C. Sampath, S. C. Sampath, C. Mosci et al., “Detection of osseous metastasis by18F-NaF/18F-FDG PET/CT versus CT alone,” Clinical Nuclear Medicine, vol. 40, no. 3, pp. e173–e177, 2015.
N. Withofs, F. Cousin, T. Tancredi, Simoni P., De Prijck B., Hafraoui K. et al., “Comparison of combined whole-body [18F]NaF and [18F]FDG PET/CT versus MRI for the detection of myeloma lesions,” Journal of Nuclear Medicine, vol. 57, supplement 2, article 606, 2016.
C. Sachpekidis, J. Hillengass, H. Goldschmidt et al., “Treatment response evaluation with18F-FDG PET/CT and 18FNaF PET/CT in multiple myeloma patients undergoing highdose chemotherapy and autologous stem cell transplantation,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 44, no. 1, pp. 50–62, 2017.
E. Otjacques, M. Binsfeld, A. Noel, Y. Beguin, D. Cataldo, and J. Caers, “Biological aspects of angiogenesis inmultiplemyeloma,” International Journal of Hematology, vol. 94, no. 6, pp. 505–518, 2011.
L. Rasche, E. Angtuaco, J. E. McDonald et al., “Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography inmultiplemyeloma,” Blood, vol. 130, no. 1, pp. 30–34, 2017.
M. Tucci, S. Stucci, C. Felici et al., “Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells,” British Journal of Haematology, vol. 173, no. 1, pp. 59–69, 2016.